Skip to main content
Clinical Trials/NCT01975272
NCT01975272
Terminated
Phase 4

The Value of Iron Treatment for Postoperative Obstetric Patients With Anemia: a Randomized Double Blind Controlled Trial

Maastricht University Medical Center2 sites in 1 country27 target enrollmentMarch 2, 2015

Overview

Phase
Phase 4
Intervention
Ferinject
Conditions
Postoperative Anaemia
Sponsor
Maastricht University Medical Center
Enrollment
27
Locations
2
Primary Endpoint
Hemoglobin
Status
Terminated
Last Updated
3 years ago

Overview

Brief Summary

The purpose of this study is to determine whether oral or intravenous iron is effective in the treatment of anaemia (iron-poor blood) after caesarean section.

Detailed Description

Anemia after caesarean section is often treated with iron therapy to ensure that the hemoglobin will return to normal more rapidly. Scientific evidence for this action is limited. Several studies, in which iron therapy was given after orthopaedic or cardiac surgery, show that after 6 to 10 weeks the hemoglobin was not significantly different between patients treated with oral preparations and patients treated with a placebo. These studies have not examined the hemoglobin level during the first few weeks after surgery including the quality of life analysis. The purpose of this double blind randomized controlled trial therefore is to examine the effect of both oral iron therapy and intravenous iron therapy on hemoglobin level and on the quality of life during the first few weeks postcaesarean in patients with a moderate anemia.

Registry
clinicaltrials.gov
Start Date
March 2, 2015
End Date
June 21, 2018
Last Updated
3 years ago
Study Type
Interventional
Study Design
Parallel
Sex
Female

Investigators

Responsible Party
Sponsor

Eligibility Criteria

Inclusion Criteria

  • Gynecological surgery
  • Hb 5-7 mmol/L

Exclusion Criteria

  • Pregnancy
  • Oncological operations
  • Infections (PID)
  • Diagnostic procedures: level 1 laparoscopies (diagnostic, sterilization, tubal testing; Hysteroscopies
  • Smaller therapeutic procedures: large loop excision of transformation zone (LLETZ), Conization,
  • Small vulvar / vaginal operations such as (cysts, labia correction)
  • Endometrial ablation
  • Legal incapacity
  • The patient has used pre-operatively an iron preparation and / or blood transfusion or during the surgery
  • Hematologic disorders

Arms & Interventions

Ferinject

Once an infusion of Ferinject 1000 mg, 1 day after surgery

Intervention: Ferinject

Ferinject

Once an infusion of Ferinject 1000 mg, 1 day after surgery

Intervention: Placebo for ferrous fumarate

Ferrous fumarate

2 times a day 200 mg ferrous fumarate, starting 24-48 hours after surgery

Intervention: Ferrous fumarate

Ferrous fumarate

2 times a day 200 mg ferrous fumarate, starting 24-48 hours after surgery

Intervention: Placebo for ferinject

Placebo infusion and tablets

Patient will get a once a placebo infusion (250 ml NaCl), one day after surgery, and 60 placebo tablets for 30 days (2 tablets a day), starting 24-48 hours after surgery

Intervention: Placebo for ferrous fumarate

Placebo infusion and tablets

Patient will get a once a placebo infusion (250 ml NaCl), one day after surgery, and 60 placebo tablets for 30 days (2 tablets a day), starting 24-48 hours after surgery

Intervention: Placebo for ferinject

Outcomes

Primary Outcomes

Hemoglobin

Time Frame: 3 weeks postoperative

Serum hemoglobin level

Secondary Outcomes

  • Serum Hepcidin(3 weeks postoperative)
  • Serum Ferritin(3 weeks postoperative)

Study Sites (2)

Loading locations...

Similar Trials